Peer Exchange

Burden of HIV in the USA and Associated Symptoms

Screening Recommendations for HIV and Risk Stratification

PrEP Therapy for High-Risk HIV Candidates

Safety Profiles of FDA-Approved PrEP Agents

State Medicaid Reimbursement for Routine HIV Screening

Rapid Initiation of HIV Treatment With ART

Factors Considered in Choosing Initial HIV Therapeutic Regimen

Safety Profile and Costs of Initial HIV Therapeutic Regimen

Switching Therapies in Patients Who Are Successfully Treated

Virological Failure or Rebound to HIV Therapies

Emerging Treatment Options for HIV

Drug Resistance or Intolerance to HIV Therapy

Long-Acting Injectables to Treat HIV

Long-Acting Injectables as PrEP Therapy

The HIV Treatment Landscape

HIV Screening and Diagnosis

HIV Pre-Exposure Prophylaxis Therapy

HIV Treatment: Initiation, Adherence, and Accessibility

HIV US Preventive Task Force Screening Recommendations

HIV: Undetectable Equals Untransmittable

HIV Therapy Selection for the General Population

HHS vs IAS-USA Guidelines for HIV

HIV Treatment Options for Pregnant Women

Dolutegravir + Rilpivirine Combination Therapy for HIV

The Difficulty of Switching ART Regimens in HIV

Recommended HIV-Monitoring Approach for Stable Patients

Virological Failure and Incomplete Response in HIV

Significance of Low-Level Viremia Indication in HIV

HIV Long-Acting Injectable Therapies in Development

HIV Noninjectable Long-Acting Therapies in Development

An Overview of ABSSSI

Understanding the Prevalence of ABSSSI in the Community

ABSSSI: Standard Protocol of Admission and Treatment

Cost Considerations of IV Antibiotics for ABSSSI

Oral Antibiotic Compliance for ABSSSI

Treatment of ABSSSI: Inpatient Versus Outpatient

ABSSSI: Outpatient Parenteral Antibiotic Therapy

Determining the Severity of ABSSSI

Lipoglycopeptide Therapies for Gram-Positive Infections

Gram-Positive ABSSSI: Early Identification and Follow-Up

ABSSSI Case Scenarios for OPAT

Trends of ABSSSI Incidence in the Community

Establishing Real-World Protocols for OPAT

OPAT Protocols: Navigating Challenges

Lipoglycopeptide Antibiotics for ABSSSI: Education

Standard Protocol for the Treatment of ABSSSI

Cost Considerations for the Treatment of ABSSSI

Risk Stratification for ABSSSI

Long-Acting Lipoglycopeptide Antibiotics for ABSSSI

Establishing a Protocol for OPAT

Future of OPAT for ABSSSI

<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?

<i>Pseudomonas</i> Infections: Matching Causes and Prevention

<i>Pseudomonas</i> Infections in the ICU Versus on the Floor

<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics

Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection

Classes and Agents Available to Treat <i>Pseudomonas</i> Infections

<i>Pseudomonas</i> Infections Continue to Acquire Resistance, Complicating Treatment

Exploring Cephalosporin/&#946;-Lactamase Inhibitor Combinations for Treatment of <i>Pseudomonas</i>

Exploring Appropriate Treatment Protocols for <i>Pseudomonas</i> Infections

Core Challenges in <i>Pseudomonas</i> Treatment Protocol

<i>Pseudomonas</i> Infections: Optimizing Diagnostic Strategies

Pseudomonas Infections: Selecting Upfront Antibiotics

<i>Pseudomonas</i> Infections: Secondary Approach to Treatment

Treating <i>Pseudomonas</i> Infections With Zerbaxa or Avycaz

Zerbaxa and Avycaz: Considerations for Treatment

The Future Treatment of Pseudomonas Infections

An Overview of Multidrug-Resistant Bacterial Infections

Understanding the Causes and Impact of MDR Infections

MDR Infections: Current Pathogen and Treatment Paradigm

Gram-Negative Nosocomial Infections: Systemic Risk

Factors in Choosing Therapy for Gram-Negative NIs

Diagnostic Tests for Gram-Negative Nosocomial Infections

Gram-Negative NIs: Vabomere and the TANGO II Study

Gram-Negative NIs: Cephalosporin/&#946;-Lactamase Inhibitors

Understanding Gram-Positive Nosocomial Infections

Selecting Lipoglycopeptide Therapy for Gram-Positive NIs

Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy

Gram-Positive NIs: Costs of Lipoglycopeptide Therapy

MDR Infections: Overview of Antimicrobial Stewardships

Importance of Technology & Data Within Antibiotic Stewardship Programs

Antimicrobial Stewardship Programs: Goals and Challenges

Multidrug-Resistant Bacterial Infections: Key Messages

The Clinical Significance of <i>Clostridium difficile</i> Infections

Understanding Why <i>Clostridium Difficile</i> Infections Occur in the Community

How <i>Clostridium difficile</i> Affects the Gastrointestinal System

Current Understanding of the Dominant Strains of <i>Clostridium difficile</i>

Risk Factors for Developing <i>Clostridium difficile</i> Infections

Community Sources of <i>Clostridium difficile</i>

When to Suspect Diarrhea is Symptom of a <i>Clostridium difficile</i> Infection

Metronidazole vs Vancomycin in Mild <i>Clostridium difficile</i> Infections

Monitoring for Treatment Response in <i>C difficile</i>

Factors That Impact <i>C difficile</i> Infection Recurrence

Fidaxomicin in the Treatment of <i>Clostridium difficile</i> Infections

Costs of Care Considerations in <i>Clostridium difficile</i>

<i>Clostridium difficile</i>: The Role of Bezlotoxumab

Fecal Transplantation in <i>Clostridium difficile</i>

<i>Clostridium Difficile</i>: Avoiding High-Risk Antibiotics

Reducing <i>Clostridium Difficile</i> Infection Rates